人工血液:2028年までの世界市場Artificial Blood: Global Markets to 2028 レポートの範囲 本調査の調査範囲は、人工血液の世界市場を網羅し、研究開発、臨床試験結果、承認状況、人工血液製品の潜在的な商業需要など、市場の様々な重要側面に焦点を当てている。レポートには、人工酸... もっと見る
サマリーレポートの範囲本調査の調査範囲は、人工血液の世界市場を網羅し、研究開発、臨床試験結果、承認状況、人工血液製品の潜在的な商業需要など、市場の様々な重要側面に焦点を当てている。レポートには、人工酸素キャリア製品に関する考察も含まれています。BCCリサーチは各市場セグメントを分析し、6年間の予測を提供しています。最新レポートでは、市場の促進要因、課題、機会を分析しています。2028年の市場予測や主要市場プレイヤーの市場分析も掲載しています。本レポートには、主要企業の事業セグメント、財務、製品ポートフォリオ、最近の開発に関する詳細情報を含む企業プロフィールが掲載されています。また、新興技術、COVID-19の影響、製品分析、取引、投資見通しに関する情報も提供しています。 レポートは以下を含みます: - 41表 - 人工血液の世界市場の概要 - 2020~2022年のデータ、2023年の推定値、2028年までの複合年間成長率(CAGR)の予測による市場規模の推定と世界市場動向の分析 - 人工血液市場の製品別、用途別、地域別の市場ポテンシャルと特徴のハイライト - 市場を形成する主要な促進要因と制約要因の検討、今後の市場機会と市場を様々なセグメントとサブセグメントに予測するための注目分野についての考察 - 業界の最近の進歩、新興技術、開発に関する考察 - 業界の主要な買収と戦略的提携の評価、業界の主要サプライヤーの市場シェア分析 - Hemarina社、VirTechBio社、NuvOx Pharma社など業界主要企業の会社概要 目次Table of ContentsChapter 1 Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report What's New in This Update? Methodology Information Sources Geographic Breakdown Chapter 2 Summary and Highlights Market Overview Chapter 3 Market Overview Introduction Is There a Problem with Human Blood? Emerging Needs for Artificial Blood Artificial Blood Will Be Useful in Dealing with the Risks of Infection Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System Hurdles in the Development of Artificial Blood Products Ideal Characteristics of Artificial Blood Artificial Blood Over Human Blood Applications Surgeries Emergency Resuscitation For Short-term Use Where More Effective Than Human Blood Rejections Due to Religious Beliefs Challenges in Artificial Blood Development Chapter 4 Market Dynamics Drivers Increasing Demand for Blood Transfusions Risks and Challenges Associated with Blood Transfusions Shortage of Blood Supply Barriers Low Rate of Product Approvals Product Acceptance Product Pricing Opportunities Impact of COVID-19 Chapter 5 Artificial Blood by Source Introduction Artificial Blood Developed from Human Blood Artificial Blood Developed from Animal Blood Artificial Blood Developed Using Recombinant Technology Surface Modified Hemoglobin Cross-Linked Hemoglobin Polymerized Hemoglobin Encapsulation Genetically Engineered Recombinant Hemoglobin Natural Hemoglobin Chapter 6 Artificial Blood by Type Introduction Perfluorocarbon Emulsions General Characteristics of Perfluorocarbons Emulsion Selection Historical Developments of Perfluorocarbon Emulsions First Generation of PFCs Second Generation of PFCs Third Generation of PFCs Hemoglobin-based Oxygen Carriers General Characteristics of HBOCs Historical Events: Hemoglobin Solutions Chapter 7 Market Estimation Introduction Potential Market for Artificial Blood Artificial Blood Market, by Source Blood (Animal/Human) Synthetic Polymers Artificial Blood Market, by Type Hemoglobin-based Oxygen Carriers Perfluorocarbon-based Products Artificial Blood Market, by Region North America Europe Emerging Markets Chapter 8 Emerging Technologies and Developments Overview Emerging Technologies Nanocapsule Technology Stem Cells Other Ongoing Research for Blood Substitutes Chapter 9 Product Analysis Introduction Product Safety Product Effectiveness Product Cost Legal Implications Product Analysis of Some of the Products Under Development Hemopure HemO2life HemoTech NanO2 (DDFPe) Sanguinate Vidaphor Clinical Trials Product Description of Some of the Products in Preclinical and Early Phase I Stage ErythroMer Hemoglobin vesicles OxyVita OxyBridge Chapter 10 Patent Analysis Introduction FDA Regulation FDA Good Manufacturing Practices and Reporting Patent Analysis Chapter 11 Competitive Intelligence Strategic Developments Competitive Analysis Chapter 12 Company Profiles AURUM BIOSCIENCES ERYPHARM HEMOGLOBIN OXYGEN THERAPEUTICS LLC. HEMARINA KALOCYTE INC. NANO SANGUIS S.A NUVOX PHARMA LLC. PROLONG PHARMACEUTICALS, LLC RED C BIOTECH VIRTECH BIO
SummaryReport Scope: Table of ContentsTable of ContentsChapter 1 Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report What's New in This Update? Methodology Information Sources Geographic Breakdown Chapter 2 Summary and Highlights Market Overview Chapter 3 Market Overview Introduction Is There a Problem with Human Blood? Emerging Needs for Artificial Blood Artificial Blood Will Be Useful in Dealing with the Risks of Infection Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System Hurdles in the Development of Artificial Blood Products Ideal Characteristics of Artificial Blood Artificial Blood Over Human Blood Applications Surgeries Emergency Resuscitation For Short-term Use Where More Effective Than Human Blood Rejections Due to Religious Beliefs Challenges in Artificial Blood Development Chapter 4 Market Dynamics Drivers Increasing Demand for Blood Transfusions Risks and Challenges Associated with Blood Transfusions Shortage of Blood Supply Barriers Low Rate of Product Approvals Product Acceptance Product Pricing Opportunities Impact of COVID-19 Chapter 5 Artificial Blood by Source Introduction Artificial Blood Developed from Human Blood Artificial Blood Developed from Animal Blood Artificial Blood Developed Using Recombinant Technology Surface Modified Hemoglobin Cross-Linked Hemoglobin Polymerized Hemoglobin Encapsulation Genetically Engineered Recombinant Hemoglobin Natural Hemoglobin Chapter 6 Artificial Blood by Type Introduction Perfluorocarbon Emulsions General Characteristics of Perfluorocarbons Emulsion Selection Historical Developments of Perfluorocarbon Emulsions First Generation of PFCs Second Generation of PFCs Third Generation of PFCs Hemoglobin-based Oxygen Carriers General Characteristics of HBOCs Historical Events: Hemoglobin Solutions Chapter 7 Market Estimation Introduction Potential Market for Artificial Blood Artificial Blood Market, by Source Blood (Animal/Human) Synthetic Polymers Artificial Blood Market, by Type Hemoglobin-based Oxygen Carriers Perfluorocarbon-based Products Artificial Blood Market, by Region North America Europe Emerging Markets Chapter 8 Emerging Technologies and Developments Overview Emerging Technologies Nanocapsule Technology Stem Cells Other Ongoing Research for Blood Substitutes Chapter 9 Product Analysis Introduction Product Safety Product Effectiveness Product Cost Legal Implications Product Analysis of Some of the Products Under Development Hemopure HemO2life HemoTech NanO2 (DDFPe) Sanguinate Vidaphor Clinical Trials Product Description of Some of the Products in Preclinical and Early Phase I Stage ErythroMer Hemoglobin vesicles OxyVita OxyBridge Chapter 10 Patent Analysis Introduction FDA Regulation FDA Good Manufacturing Practices and Reporting Patent Analysis Chapter 11 Competitive Intelligence Strategic Developments Competitive Analysis Chapter 12 Company Profiles AURUM BIOSCIENCES ERYPHARM HEMOGLOBIN OXYGEN THERAPEUTICS LLC. HEMARINA KALOCYTE INC. NANO SANGUIS S.A NUVOX PHARMA LLC. PROLONG PHARMACEUTICALS, LLC RED C BIOTECH VIRTECH BIO
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(生化学的薬物)の最新刊レポートBCC Research社のライフサイエンス分野での最新刊レポート本レポートと同じKEY WORD(artificial)の最新刊レポートよくあるご質問BCC Research社はどのような調査会社ですか?BCCリサーチ(BCC Research)は1971年に設立され、様々な業界経験を持つアナリストと編集者によりトップクラスの市場情報源を長年提供している調査会社です。 設立初期は先端材料とプラ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/20 10:28 158.95 円 165.20 円 201.28 円 |